Alkermes said that schizophrenia patients treated with ALKS 3831 reported significantly less weight gain compared to the most commonly prescribed antipsychotic currently in us, achieving the Phase 3’s main goal and paving the way for the company to seek regulatory approval in mid-2019. Though Alkermes was “very much in need of some good news,” Adam Feuerstein of STATNews says the company could find it difficult to convince insurance companies to offer liberal reimbursement terms for a more expensive antipsychotic when there are cheaper, generic options on the market already, some of which don’t claim weight gain as a side effect.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.